Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Simple item page
dc.contributor.authorLi, Jingjing
dc.contributor.authorBi, Wen
dc.contributor.authorLu, Fang
dc.contributor.authorPan, Bei
dc.contributor.authorXiong, Mengqiu
dc.contributor.authorLubanga, Nasifu
dc.contributor.authorNie, Zhenlin
dc.contributor.authorHe, Bangshun
dc.date.accessioned2023-07-23T21:41:19Z
dc.date.available2023-07-23T21:41:19Z
dc.date.issued2023-06-05
dc.description.abstractE2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data. PubMed, Web of Science and CNKI database were searched until May 31st, 2022 using keywords to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of the hazard ratio and 95% confidence interval was calculated with Stata17.0 software. A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I2 = 95.3%, *PHeterogeneity = 0.000) and disease-free survival (HR = 1.41, I2 = 95.2%, *PHeterogeneity = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper.en_US
dc.description.sponsorshipThis work was supported by the National Nature Science Foundation of China (82073288).en_US
dc.identifier.citationLi, J., Bi, W., Lu, F., Pan, B., Xiong, M., Lubanga, N., Nie, Z., & He, B.(2023). Prognostic role of E2F1 gene expression in human cancer: a meta-analysis. BMC cancer, 23(1), 509.en_US
dc.identifier.urihttps://dir.muni.ac.ug/handle/20.500.12260/547
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.subjectBreast canceren_US
dc.subjectCanceren_US
dc.subjectDisease-free survivalen_US
dc.subjectE2F1en_US
dc.subjectGene expressionen_US
dc.subjectMeta-analysisen_US
dc.subjectOverall survivalen_US
dc.subjectPrognosisen_US
dc.titlePrognostic role of E2F1 gene expression in human cancer: a meta-analysisen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lubanga_Article_2023_3.pdf
Size:
2.62 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles